The effect of long-term intermittent trimethoprim/ulfamethoxazole treatment on recurrence of toxoplamic retinochoroiditi

PURPOE: To determine the effect of long-term intermittent trimethoprim/ulfamethoxazole treatment on recurrence of toxoplamic retinochoroiditi. DEIGN: Propective randomized open-labeled interventional clinical trial. METHOD: A total of 124 patient with a hitory of recurrent toxoplamic retinochoroiditi were randomized to treatment with one tablet of trimethoprim (160 mg)/ulfamethoxazole (800 mg) (Bactrim F; Roche Pharmaceutical, Rio de Janeiro, Brazil) every 3 day (61 patient) or to obervation without treatment (63 patient) and were followed monthly for up to 20 conecutive month for clinical ign of dieae recurrence. A recurrence wa defined a a new focu of necrotizing retinochoroiditi with active inflammation either adjacent to or remote from preexiting retinochoroidal car. REULT: Recurrence developed in four (6.6%) treated patient and in 15 (23.8%) control (P = .01). Treatment wa dicontinued prematurely in four patient becaue of mild drug reaction. CONCLUION: Long-term intermittent treatment with trimethoprim/ulfamethoxazole can reduce the rate of recurrent toxoplamic retinochoroiditi.